Drugs / soluble beta-1,3/1,6-glucan
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00790322 | Oct 2008 → Feb 2010 | head and neck cancer, mucositis | Biotec Pharmacon ASA | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | soluble beta-1,3/1,6-glucan | “The objective of the study is to evaluate the efficacy and safety of soluble beta-1,3/1,6-glucan (SBG) on oral mucositis compared to placebo in head and neck cancer patients...” NCT00790322 ↗ |
| Known as | SBG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00790322 ↗ |
| Route | Oral | “Soluble beta-1,3/1,6-glucan is a solution for oral use” NCT00790322 ↗ |